RALEIGH – Investors continue to pour money into Bryn Pharma, the Raleigh-based startup developing an alternative to the EpiPen.
According to a securities filing, 127 backers have now invested $26 million in the company. But Bryn aims to raise another $4 million, according to the filing.
Bryn disclosed $17 million in funding early in 2019.
The company is owned and operated by Dr. David Dworaczyk, who is responsible for all aspects of the organization and directing the growth and success of the company. Bryn Pharma is producing an alternative to the EpiPen.
“Our mission is simple – to empower patients with a life-saving device that is small enough to comfortably fit in your pocket and easy to use in the event of an anaphylactic attack,” the company says.
The Food and Drug Administration granted the Bryn Intranasal Epinephrine Spray (BRYN-NDS1C) Fast Track designation early in 2019.
The company is developing and manufacturing an innovative needleless nasal solution for the administration of emergency epinephrine.
Bryn Pharma, formerly Epi-Now LLC, raised $9.2 million in securities sold to 72 investors, according to a 2018 filing with the SEC.
Original Post By: WRAL TechWire